Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 6/2016

22.03.2016 | Original Article

Predicting Individual Survival After Hepatectomy for Hepatocellular Carcinoma: a Novel Nomogram from the “HCC East & West Study Group”

verfasst von: Guido Torzilli, Matteo Donadon, Jacques Belghiti, Norihiro Kokudo, Tadatoshi Takayama, Alessandro Ferrero, Gennaro Nuzzo, Jean-Nicolas Vauthey, Michael A. Choti, Eduardo De Santibanes, Masatoshi Makuuchi

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Introductions

Different staging systems have been devised for patients undergoing resection for hepatocellular carcinoma (HCC) with disparate results. The aim of this study was to create a new nomogram to predict individual survival after hepatectomy for HCC.

Methods

Based on the “Hepatocellular Carcinoma: Eastern & Western Experiences Network,” data from 2046 patients who underwent HCC resections at ten centers were reviewed. Patient survival was analyzed with Cox-regression analysis to construct a unique nomogram and contour plots to predict survival.

Results

The nomograms built on the multivariate analyses, which showed that the independent predictors were tumor size, tumor number, vascular invasion, cirrhosis, preoperative bilirubin value, and esophageal varices, showed good calibration and discriminatory abilities with C-index value of 0.62 (95 % CI, 0.59–0.69) and 0.61 (95 % CI, 0.56–0.64) for overall and disease-free survival, respectively. The 5-year survival contour plots showed that the presence of vascular invasion was associated with decreased survival, regardless of the tumor number or size. Cirrhosis and varices were equally associated with decreased survival, according to the tumor number or size.

Conclusions

These nomograms accurately predict individual prognosis after HCC resection and support an expansion of the selection criteria for resection. They offer useful guidance to clinicians for individual survival prediction.
Literatur
1.
Zurück zum Zitat Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009;44(S19):96–101.CrossRefPubMed Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009;44(S19):96–101.CrossRefPubMed
2.
Zurück zum Zitat Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15(S4):5–13.CrossRefPubMed Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15(S4):5–13.CrossRefPubMed
3.
Zurück zum Zitat Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35–43.CrossRefPubMed Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35–43.CrossRefPubMed
4.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693–699.CrossRefPubMed Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693–699.CrossRefPubMed
5.
Zurück zum Zitat Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013;257:929–37.CrossRefPubMed Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013;257:929–37.CrossRefPubMed
7.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430.CrossRefPubMed Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430.CrossRefPubMed
8.
Zurück zum Zitat Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–338.CrossRefPubMed Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–338.CrossRefPubMed
9.
Zurück zum Zitat Terminology Committee of the IHPBA (authors). Terminology of liver anatomy and resections. HPB Surg 200;2:333–339. Terminology Committee of the IHPBA (authors). Terminology of liver anatomy and resections. HPB Surg 200;2:333–339.
10.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Groenwold RH, Hak E, Hoes AW. Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies. J Clin Epidemiol 2009;62:22–28.CrossRefPubMed Groenwold RH, Hak E, Hoes AW. Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies. J Clin Epidemiol 2009;62:22–28.CrossRefPubMed
12.
Zurück zum Zitat Harrell Jr. FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–387.CrossRefPubMed Harrell Jr. FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–387.CrossRefPubMed
13.
Zurück zum Zitat Bruix J, Fuster J. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group. Ann Surg 2015;262:e30.CrossRefPubMed Bruix J, Fuster J. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group. Ann Surg 2015;262:e30.CrossRefPubMed
14.
Zurück zum Zitat Mazzaferro V, Roayaie S, Poon R, et al. Dissecting EASL/AASLD recommendations with a more careful knife: a comment on “surgical misinterpretation” of the BCLC staging system. Ann Surg 2015;262:e17-18.CrossRefPubMed Mazzaferro V, Roayaie S, Poon R, et al. Dissecting EASL/AASLD recommendations with a more careful knife: a comment on “surgical misinterpretation” of the BCLC staging system. Ann Surg 2015;262:e17-18.CrossRefPubMed
15.
Zurück zum Zitat Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018–22.CrossRefPubMed Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018–22.CrossRefPubMed
16.
Zurück zum Zitat Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62–67.CrossRefPubMed Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62–67.CrossRefPubMed
17.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.CrossRefPubMed
18.
Zurück zum Zitat Torzilli G, Belghiti J, Kokudo N, et al. Reply to the Letter to the Editor titled “Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on ‘Surgical Misinterpretation’ of the BCLC Staging System”: Real Misinterpretation or Lack of Clarity within the BCLC? Ann Surg 2015;262:e18-19.CrossRefPubMed Torzilli G, Belghiti J, Kokudo N, et al. Reply to the Letter to the Editor titled “Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on ‘Surgical Misinterpretation’ of the BCLC Staging System”: Real Misinterpretation or Lack of Clarity within the BCLC? Ann Surg 2015;262:e18-19.CrossRefPubMed
19.
Zurück zum Zitat Torzilli G, Belghiti J, Kokudo N, et al. Reply to the letter to the editor entitled “A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group”: when the study setting “ignores” the patients. Ann Surg 2015;262:e30-31.CrossRefPubMed Torzilli G, Belghiti J, Kokudo N, et al. Reply to the letter to the editor entitled “A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group”: when the study setting “ignores” the patients. Ann Surg 2015;262:e30-31.CrossRefPubMed
20.
Zurück zum Zitat Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005; 03:402–408.CrossRef Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005; 03:402–408.CrossRef
21.
Zurück zum Zitat Sternberg CN. Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol 2006;24:3819–3820.CrossRefPubMed Sternberg CN. Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol 2006;24:3819–3820.CrossRefPubMed
22.
Zurück zum Zitat Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28:2437–2444.CrossRefPubMed Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28:2437–2444.CrossRefPubMed
23.
Zurück zum Zitat Cho CS, Gonen M, Shia J, et al. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg 2008;206:281–291.CrossRefPubMed Cho CS, Gonen M, Shia J, et al. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg 2008;206:281–291.CrossRefPubMed
24.
Zurück zum Zitat Shim JH, Jun MJ, Han S, et al. Prognostic Nomograms for Prediction of Recurrence and Survival After Curative Liver Resection for Hepatocellular Carcinoma. Ann Surg 2014;261:939–946.CrossRef Shim JH, Jun MJ, Han S, et al. Prognostic Nomograms for Prediction of Recurrence and Survival After Curative Liver Resection for Hepatocellular Carcinoma. Ann Surg 2014;261:939–946.CrossRef
25.
Zurück zum Zitat Edge SB (2009) AJCC Cancer Staging Manual (ed 7) Springer-Verlag, New York. Edge SB (2009) AJCC Cancer Staging Manual (ed 7) Springer-Verlag, New York.
26.
Zurück zum Zitat Liver Cancer Study Group of Japan, Okamoto E (1997) Classification of Primary Liver Cancer. Liver Cancer Study Group of Japan, Okamoto E (1997) Classification of Primary Liver Cancer.
27.
Zurück zum Zitat Capussotti L, Ferrero A, Vigano L, et al. Portal hypertension: contraindication to liver surgery? World J Surg 2006;30:992–999.CrossRefPubMed Capussotti L, Ferrero A, Vigano L, et al. Portal hypertension: contraindication to liver surgery? World J Surg 2006;30:992–999.CrossRefPubMed
28.
Zurück zum Zitat Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009; 250:922–928.CrossRefPubMed Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009; 250:922–928.CrossRefPubMed
29.
Zurück zum Zitat Torzilli G, Donadon M, Marconi M, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg 2008;143:1082–1090.CrossRefPubMed Torzilli G, Donadon M, Marconi M, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg 2008;143:1082–1090.CrossRefPubMed
30.
Zurück zum Zitat Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995–2004.CrossRefPubMedPubMedCentral Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995–2004.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Lee SC, Tan HT, Chung MC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2014;20:3112–3124.CrossRefPubMedPubMedCentral Lee SC, Tan HT, Chung MC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2014;20:3112–3124.CrossRefPubMedPubMedCentral
Metadaten
Titel
Predicting Individual Survival After Hepatectomy for Hepatocellular Carcinoma: a Novel Nomogram from the “HCC East & West Study Group”
verfasst von
Guido Torzilli
Matteo Donadon
Jacques Belghiti
Norihiro Kokudo
Tadatoshi Takayama
Alessandro Ferrero
Gennaro Nuzzo
Jean-Nicolas Vauthey
Michael A. Choti
Eduardo De Santibanes
Masatoshi Makuuchi
Publikationsdatum
22.03.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 6/2016
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-016-3132-0

Weitere Artikel der Ausgabe 6/2016

Journal of Gastrointestinal Surgery 6/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.